Originally published as JCO Early Release 10.1200/JCO.2005.03.065 on December 21 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gadducci, A. Articles by Cristofani, R. Search for Related Content PubMed PubMed Citation Articles by Gadducci, A. Articles by Cristofani, R. Related Articles Related Editorials Social Bookmarking                            What's this?

Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study

From the Department of Gynecology and Obstetrics, Department of Experimental Pathology, University of Pisa; Institute of Clinical Physiology, National Research Council, Pisa; Department of Gynecology and Obstetrics, University of Brescia, Brescia; Department of Gynecology and Obstetrics, University of Turin, Turin; and Department of Gynecology and Obstetrics, University of Padua, Padua; European Institute of Oncology, Milan, Italy

Address reprint requests to Angiolo Gadducci, MD, Department of Procreative Medicine, Division of Gynecology and Obstetrics, University of Pisa, Via Roma 56, Pisa, 56127, Italy; e-mail: a.gadducci{at}obgyn.med.unipi.it

PURPOSE: To assess whether the interval from primary surgery to the start of taxane- plus platinum-based chemotherapy has any impact on the clinical outcome of advanced ovarian cancer patients.

PATIENTS AND METHODS: The study was conducted on 313 patients who underwent surgery followed by taxane- plus platinum-based chemotherapy. The median follow-up of survivors was 30.7 months (range, 6 to 109 months).

RESULTS: The 25%, 50%, and 75% quantiles of intervals from surgery to the start of chemotherapy were 11, 21, and 31 days, respectively. After the sixth cycle, 102 patients achieved a pathologic complete response at second-look surgery and 98 obtained a clinical complete response but were not submitted to second-look surgery. Taking into consideration the best assessed response, a complete (either clinical or pathologic) response was found in 200 patients. Residual disease ( 1 v > 1 cm; P < .0001) and ascites (absent v present; P = .003) were independent predictive factors for achieving a complete response, whereas residual disease (P = .001) and stage (IIc to III v IV; P = .04) were independent prognostic variables for survival. Conversely, statistical analyses failed to detect significant differences in complete response rates and survival among patients with an interval from surgery to chemotherapy shorter than 11 days, 12 to 21 days, 22 to 31 days, and longer than 31 days.

CONCLUSION: The interval from surgery to the start of taxane- plus platinum-based chemotherapy seems to have neither a predictive value for response to treatment nor a prognostic relevance for survival of advanced ovarian cancer patients.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorials

• Perioperative Morbidity and the Rush to Chemotherapy
  William P. McGuire, III
  JCO 2005 23: 665-666 [Full Text]
• Perioperative Morbidity and the Rush to Chemotherapy
  William P. McGuire, III
  JCO 2005 23: 665-666 [Full Text]

This article has been cited by other articles:

				W. P. McGuire III Perioperative Morbidity and the Rush to Chemotherapy J. Clin. Oncol., February 1, 2005; 23(4): 665 - 666. [Full Text] [PDF]